Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$25.3M
Filings
268
Firms Hired
9
Active Period
2001–2019
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Cancer Drug Parity Act of 2019
2019 · fourth_quarter · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: H.R. 1730
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: H.R. 2279
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: HR 965
Prescription Drug Pricing Reduction Act of 2019
2019 · fourth_quarter · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: S. 2543
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: S.2546
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · fourth_quarter · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: S. 340
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279 / S.2546, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $400,000 · Firm income: —
Matched citations: S. 741
Cancer Drug Parity Act of 2019
2019 · fourth_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1730
Elijah E. Cummings Lower Drug Costs Now Act
2019 · fourth_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 965
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 985
Clean Water Through Green Infrastructure Act
2019 · fourth_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2456
Prescription Drug Pricing Reduction Act of 2019
2019 · fourth_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 2543
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · fourth_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 340
Cancer Drug Parity Act of 2019
2019 · fourth_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 741
Cancer Drug Parity Act of 2019
2019 · third_quarter · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: H.R. 1730
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: H.R. 2279
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: HR 965
Prescription Drug Pricing Reduction Act of 2019
2019 · third_quarter · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: S. 2543
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: S. 2546
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · third_quarter · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: S. 340
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Client expense: $900,000 · Firm income: —
Matched citations: S. 741
Cancer Drug Parity Act of 2019
2019 · third_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1730
Elijah E. Cummings Lower Drug Costs Now Act
2019 · third_quarter · Firm: BAKER & HOSTETLER LLP
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3
Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid. Medicare reimbursement for transformative therapies. H.R. 3, the Lower Drug Costs Now Act. S. 2543, the Prescription Drug Price Reduction Act. S. 2456, the Safe Step Act. H.R. 1730, the Cancer Drug Parity Act. S. 741, the Cancer Drug Parity Act. H.R. 985, the FAST Generics Act. S. 340, the CREATES Act. H.R. 965, the CREATES Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 965
Source: Senate LDA